Emerging data suggest this peptide, a retatrutide review dual activator targeting both GLP-1 and another hormone, appears to represent a significant step forward for body loss . Initial patient trials have demonstrated substantial reductions in visceral mass , conceivably outperforming existing body composition treatments. Nevertheless , more asses